Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-28T02:12:07.546Z Has data issue: false hasContentIssue false
  • English
  • Français

Aminoadamantane-resistant strains of influenza A2 virus

Published online by Cambridge University Press:  15 May 2009

J. S. Oxford  and
C. W. Potter
J. S. Oxford
Affiliation:
Department of Microbiology, John Curtin School of Medical Research, Australian National University, Canberra, A.C.T. Australia and Department of Medical Microbiology, The University, Sheffield, England
C. W. Potter
Affiliation:
Department of Microbiology, John Curtin School of Medical Research, Australian National University, Canberra, A.C.T. Australia and Department of Medical Microbiology, The University, Sheffield, England
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

After one passage of influenza A2/Singapore/l/57 virus in mice treated with 150 mg./kg./day of aminoadamantane, a partially drug-resistant strain of virus was detected in 1 of 12 mice. The isolation rate of aminoadamantane-resistant viruses increased to 8 after three passages in drug-treated mice. Some virus strains showed a 500-fold increase in resistance to aminoadamantane and to the structurally related compounds α-methyl-1-adamantane methylamine and 2-adamantanamine sulphate. No aminoadamantane-resistant viruses were detected after passage of influenza four times in mice treated with lower (15 or 1·5 mg./kg./day) concentrations of aminoadamantane. Aminoadamantane had no detectable effect on the development of lung lesions in mice infected with the drug-resistant influenza strain, whereas lung lesions were reduced in aminoadamantane treated mice infected with a control strain of influenza A2/Singapore virus. No differences were detected in the buoyant density in caesium chloride, morphology or serology between control and aminoadamantane-resistant strains of virus. These drug-resistant influenza viruses may be useful for detailed studies of the mode of action of aminoadamantane.

Type
Research Article
Information
Journal of Hygiene , Volume 71 , Issue 2 , June 1973 , pp. 227 - 236
Copyright
Copyright © Cambridge University Press 1973

References

REFERENCES

Eggers, H. J. & Tamm, I. (1961). Spectrum and characteristics of the virus inhibitory action of 2-(α-hydroxybenzyl) benzimidazole. Journal of Experimental Medicine 113, 657–82.CrossRefGoogle ScholarPubMed
Eggers, H. J. & Tamm, I. (1963). Drug dependence of enteroviruses: Variants of Coxsackie A9 and ECHO 13 viruses that require 2-(α-hydroxybenzyl) benzimidazole for growth. Virology 20, 62–74.CrossRefGoogle Scholar
Finter, N. B. (1964). Quantitative haemadsorption, a new assay technique. Virology 24, 589–97.CrossRefGoogle ScholarPubMed
Galbraith, A. W., Oxford, J. S., Schild, G. C. & Watson, G. I. (1970). Protective effect of aminoadamantane on influenza A2 infections in the family environment. Annals of the New York Academy of Sciences 173, 29–43.CrossRefGoogle Scholar
Galbraith, A. W., Oxford, J. S., Schild, G. C., Potter, C. W. & Watson, G. I. (1971). Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A2/Hong Kong infection. Lancet ii, 113–15.CrossRefGoogle Scholar
Hoffmann, C. E., Neumayer, E. M., Haff, R. F. & Goldsby, R. A. (1965). Mode of action of the antiviral activity of amantadine in tissue culture. Journal of Bacteriology 90, 623–8.CrossRefGoogle ScholarPubMed
Iezzoni, D. (1970). Evaluation of amantadine hydrochloride in the treatment of A2 influenza disease. Annals of the New York Academy of Sciences 173, 10–19.Google Scholar
Kato, N. & Eggers, H. J. (1969). Inhibition of uncoating of fowl plague virus by 1-adaman-tanamine hydrochloride. Virology 37, 632–41.CrossRefGoogle ScholarPubMed
Laver, W. G. (1969). Purification of influenza virus. In Fundamental Techniques in Virology, (ed. Habel, K. and Salzman, N. P.). New York: Academic Press.Google Scholar
Long, W. F. & Olusanya, J. (1972). Adamantanamine and early events following influenza virus infection. Archiv für die gesamte Virusforschung 36, 18–22.CrossRefGoogle ScholarPubMed
Melnick, J. L., Crowther, D. & Barrera-Oro, J. (1961). Rapid development of drug resistant mutants of poliovirus. Science, New York 134, 557.CrossRefGoogle ScholarPubMed
Oxford, J. S. & Schild, G. C. (1968). Immunofluorescent studies on the inhibition of influenza A and B antigens in mammalian cell cultures by amines. Journal of General Virology 2, 377–84.CrossRefGoogle Scholar
Oxford, J. S. & Potter, C. W. (1969). A difference in the buoyant density of haemagglutinin from rubella virus strains. Journal of General Virology 5, 565–8.CrossRefGoogle Scholar
Oxford, J. S., Potter, C. W. & Logan, I. (1970). Passage of influenza strains in the presence of aminoadamantane. Annals of the New York Academy of Sciences 173, 300–13.CrossRefGoogle Scholar
Oxford, J. S., Logan, I. S. & Potter, C. W. (1970). In vivo selection of an influenza A3 strain resistant to amantadine. Nature, London 226, 82–3.CrossRefGoogle Scholar
Oxford, J. S., Potter, C. W., Mclaren, C. & Hardy, W. (1971). Inactivation of influenza and other viruses by a mixture of virucidal compounds. Applied Microbiology 21, 606–10.CrossRefGoogle ScholarPubMed
Renis, H. E. & Buthala, D. A. (1965). Development of resistance to antiviral drugs. Annals of the New York Academy of Sciences 130, 343–54.CrossRefGoogle ScholarPubMed
Schild, G. C. & Newman, R. W. (1969). Antibody against influenza A2 virus neuraminidase in human sera. Journal of Hygiene 67, 353–65.CrossRefGoogle ScholarPubMed
Subak-Sharpe, J. H., Timbury, M. C. & Williams, J. F. (1969). Rifampicin inhibits the growth of some mammalian viruses. Nature, London 222, 341–5.CrossRefGoogle ScholarPubMed